CAR T-Cell Therapy as Second-Line Treatment in Large B-Cell Lymphomas
Last Updated: Tuesday, March 15, 2022
About 30% to 40% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) experience relapse, and 10% are refractory to the regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Most relapses occur during the first 2 years. This article reviews what was learned from the randomized BELINDA, TRANSFORM, and ZUMA-7 trials.
Advertisement
News & Literature Highlights
